// App-Quantinova.ai

: Somatostatin receptor splicing variant SST5TMD4 overexpression in glioblastoma is associated to poor survival, increased aggressiveness features and somatostatin analogs resistance

Researchers

Presenter

  • Jesus Perez Gomez

Principal Investigators

  • Antonio C. Fuentes-Fayos

  • Miguel E. G-Garcia

  • Annabel Peel

  • Cristbal Blanco Acevedo

  • Juan Solivera Vela

  • Alejandro Ibez Costa

  • Manuel David Gahete Ortiz

  • Justo P. Castao

  • Ral M. Luque

Medical Centers

  • Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordova, Spain

  • Reina Sofia University Hospital, Cordoba, Spain

  • CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Cordoba, Spain

  • Cardiff University School of Medicine, Cardiff, United Kingdom

  • Reina Sofia University Hospital, Department of Neurosurgery, Córdoba, Spain

Locations

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Anaplastic astrocytoma

  • Glioblastoma

  • Solid malignancies

Biomarkers

  • Somatostatin

Drug/Treatment

  • Somatostatin

  • Pasireotide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved